Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors

The ability to detect minimal residual disease (MRD) after a curative-intent surgery or treatment is of paramount importance, because it offers the possibility to help guide the clinical decisions related adjuvant therapy. Thus, the earlier MRD is detected, the earlier potentially beneficial treatme...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lionel Larribère, Uwe M. Martens
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	liquid biopsy ctDNA minimal residual disease adjuvant therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b8daf264d4a245bcae974b1bd6f1accc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b8daf264d4a245bcae974b1bd6f1accc
record_format	dspace
spelling	oai:doaj.org-article:b8daf264d4a245bcae974b1bd6f1accc2021-11-25T17:02:47ZAdvantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors10.3390/cancers132256982072-6694https://doaj.org/article/b8daf264d4a245bcae974b1bd6f1accc2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5698https://doaj.org/toc/2072-6694The ability to detect minimal residual disease (MRD) after a curative-intent surgery or treatment is of paramount importance, because it offers the possibility to help guide the clinical decisions related adjuvant therapy. Thus, the earlier MRD is detected, the earlier potentially beneficial treatment can be proposed to patients who might need it. Liquid biopsies, and in particular the next-generation sequencing of circulating tumor DNA (ctDNA) in the blood, have been the focus of an increasing amount of research in the past years. The ctDNA detection at advanced cancer stages is practicable for several solid tumors, and complements molecular information on acquired therapy resistance. In the context of MRD, it is by definition more challenging to detect ctDNA, but it is technically achievable and provides information on treatment response and probability of relapse significantly earlier than standard imaging methods. The clinical benefit of implementing this new technique in the routine is being tested in interventional clinical trials at the moment. We propose here an update of the current use of ctDNA detection by NGS as a tool to assess the presence of MRD and improve adjuvant treatment of solid tumors. We also discuss the main limitations and medium-term perspectives of this process in the clinic.Lionel LarribèreUwe M. MartensMDPI AGarticleliquid biopsyctDNAminimal residual diseaseadjuvant therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5698, p 5698 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	liquid biopsy ctDNA minimal residual disease adjuvant therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	liquid biopsy ctDNA minimal residual disease adjuvant therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lionel Larribère Uwe M. Martens Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
description	The ability to detect minimal residual disease (MRD) after a curative-intent surgery or treatment is of paramount importance, because it offers the possibility to help guide the clinical decisions related adjuvant therapy. Thus, the earlier MRD is detected, the earlier potentially beneficial treatment can be proposed to patients who might need it. Liquid biopsies, and in particular the next-generation sequencing of circulating tumor DNA (ctDNA) in the blood, have been the focus of an increasing amount of research in the past years. The ctDNA detection at advanced cancer stages is practicable for several solid tumors, and complements molecular information on acquired therapy resistance. In the context of MRD, it is by definition more challenging to detect ctDNA, but it is technically achievable and provides information on treatment response and probability of relapse significantly earlier than standard imaging methods. The clinical benefit of implementing this new technique in the routine is being tested in interventional clinical trials at the moment. We propose here an update of the current use of ctDNA detection by NGS as a tool to assess the presence of MRD and improve adjuvant treatment of solid tumors. We also discuss the main limitations and medium-term perspectives of this process in the clinic.
format	article
author	Lionel Larribère Uwe M. Martens
author_facet	Lionel Larribère Uwe M. Martens
author_sort	Lionel Larribère
title	Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
title_short	Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
title_full	Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
title_fullStr	Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
title_full_unstemmed	Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
title_sort	advantages and challenges of using ctdna ngs to assess the presence of minimal residual disease (mrd) in solid tumors
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b8daf264d4a245bcae974b1bd6f1accc
work_keys_str_mv	AT lionellarribere advantagesandchallengesofusingctdnangstoassessthepresenceofminimalresidualdiseasemrdinsolidtumors AT uwemmartens advantagesandchallengesofusingctdnangstoassessthepresenceofminimalresidualdiseasemrdinsolidtumors
_version_	1718412798537498624

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors

Ejemplares similares